

GF/B42/EDP09 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period

The Board:

1. Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER08 (“Table 1”);
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat’s Recommendation on Additional Funding to Finance UQD from the 2017-2019 Allocation Period - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Algeria	HIV/AIDS	DZA-H-MOH	Portfolio Optimization	US\$	2,312,936	1,321,451	3,634,387
2	Ethiopia	Tuberculosis	ETH-T-FMOH	Portfolio Optimization	US\$	45,599,381	5,999,970	51,599,351
3	Ghana	Malaria	GHA-M-MOH	Portfolio Optimization	US\$	94,148,208	21,300,000	115,448,208
4	Nigeria	Tuberculosis	NGA-T-IHVN	Portfolio Optimization	US\$	29,703,883	26,288,575	55,992,458
5	Uzbekistan	Tuberculosis	UZB-T-RDC	Portfolio Optimization	US\$	19,000,831	2,958,638	21,959,469